Sunday, May 29, 2016

Neurocrine Biosciences, Inc. (NBIX) Given “Buy” Rating at Jefferies Group

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) s stock had its buy rating reiterated by research analysts at Jefferies Group in a research note issued to investors on Wednesday. They currently have a $61.00 price objective on the stock. Jefferies Group s target price suggests a potential upside of 25.08% from the stock s previous close. In other Neurocrine Biosciences news, [ ]